المؤلفون: Lalau JD; Department of Endocrinology, Diabetes Mellitus and Nutrition, Amiens University Hospital, 80054 Amiens, France; PériTox = UMR_I 01, University of Picardie Jules Verne, Amiens, France. Electronic address: Lalau.Jean-Daniel@chu-amiens.fr., Al-Salameh A; Department of Endocrinology, Diabetes Mellitus and Nutrition, Amiens University Hospital, 80054 Amiens, France; PériTox = UMR_I 01, University of Picardie Jules Verne, Amiens, France. Electronic address: Al-Salameh.Abdallah@chu-amiens.fr., Hadjadj S; Département d'Endocrinologie, Diabétologie et Nutrition, l'institut du Thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, 44093 Nantes Cedex 01, France., Goronflot T; Data Clinic, INSERM, CIC 1413, PHU 11, Nantes University Hospital, Nantes, France., Wiernsperger N; Association REMEDES, Ville-sur-Jarnioux, France., Pichelin M; Département d'Endocrinologie, Diabétologie et Nutrition, l'institut du Thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, 44093 Nantes Cedex 01, France., Allix I; Département d'Endocrinologie, Diabétologie, Nutrition, CHU Angers, Angers, France., Amadou C; Département de Diabétologie, Centre Hospitalier Sud Francilien, Corbeil Essonne, France., Bourron O; Sorbonne Université, Assistance Publique Hôpitaux de Paris, Département de Diabétologie, CHU La Pitié Salpêtrière-Charles Foix, Inserm, UMR_S 1138, Centre de Recherche des Cordeliers, Paris 06, Institute of Cardiometabolism and Nutrition ICAN, Paris, France., Duriez T; Service D'Endocrinologie, Diabétologie, CH Cholet, Cholet, France., Gautier JF; Département Diabète et Endocrinologie, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France., Dutour A; Département d'Endocrinologie et de Diabétologie, Hôpital Nord, Assistance Publique Hôpitaux de Marseille, Marseille, France., Gonfroy C; Service d'Endocrinologie, Diabétologie, CH de Pontoise, Pontoise, France., Gouet D; Service de Diabétologie, Endocrinologie, Centre Hospitalier de la Rochelle, La Rochelle, France., Joubert M; Service Diabétologie-endocrinologie, CHU Caen, Caen, France., Julier I; CH de Ales, Ales, France., Larger E; Université de Paris and AP-HP, Centre Hospitalier Universitaire de Paris, Cochin Hospital, Paris, France., Marchand L; Département d'Endocrinologie et de Diabétologie, Centre Hospitalier St. Joseph - St. Luc, Lyon, France., Marre M; Clinique Ambroise Paré Neuilly-sur-Seine, Centre de Recherches des Cordelier, Université Paris Diderot, Paris, France., Meyer L; Service d'Endocrinologie, Diabète et Nutrition, HUS - Hôpital Civil, Strasbourg, France., Olivier F; Service de Diabétologie, Centre Hospitalier de Cahors, Cahors, France., Prevost G; Département d'Endocrinologie, Diabétologie et Maladies Métaboliques, CHU de Rouen, Université de Rouen, Rouen, France., Quiniou P; CHU de Brest, Brest, France., Raffaitin-Cardin C; CH Robet Boulin de Libourne, Libourne, France., Roussel R; Département d'Endocrinologie, Diabétologie et Nutrition, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Centre de Recherche des Cordeliers, Inserm, U-1138, Université de Paris, Paris, France., Saulnier PJ; Centre d'Investigation Clinique CIC 1402, Université de Poitiers, Inserm, CHU de Poitiers, Poitiers, France., Seret-Begue D; Service de Diabétologie, CH Gonesse, Gonesse, France., Thivolet C; Centre du Diabète DIAB-eCARE, Hospices Civils de Lyon et Laboratoire CarMeN, Inserm, INRA, INSA, Université Claude Bernard Lyon 1, Lyon, France., Vatier C; Assistance Publique Hôpitaux de Paris, Saint-Antoine Hospital, Reference Center of Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Department of Endocrinology, Paris, France., Desailloud R; Department of Endocrinology, Diabetes Mellitus and Nutrition, Amiens University Hospital, 80054 Amiens, France; PériTox = UMR_I 01, University of Picardie Jules Verne, Amiens, France., Wargny M; Data Clinic, INSERM, CIC 1413, PHU 11, Nantes University Hospital, Nantes, France., Gourdy P; Département d'Endocrinologie, Diabétologie et Nutrition, CHU Toulouse, Institut des Maladies Métaboliques et Cardiovasculaires, UMR1048 Inserm/UPS, Université de Toulouse, Toulouse, France., Cariou B; Département d'Endocrinologie, Diabétologie et Nutrition, l'institut du Thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, 44093 Nantes Cedex 01, France.

مؤلفون مشاركون: CORONADO investigators

المصدر: Diabetes & metabolism [Diabetes Metab] 2021 Sep; Vol. 47 (5), pp. 101216. Date of Electronic Publication: 2020 Dec 10.

نوع المنشور: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Masson Country of Publication: France NLM ID: 9607599 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1780 (Electronic) Linking ISSN: 12623636 NLM ISO Abbreviation: Diabetes Metab Subsets: MEDLINE

مواضيع طبية MeSH: COVID-19/*mortality , Diabetes Mellitus, Type 2/*drug therapy , Diabetes Mellitus, Type 2/*mortality , Hypoglycemic Agents/*therapeutic use , Metformin/*therapeutic use, Aged ; Aged, 80 and over ; COVID-19/complications ; COVID-19/therapy ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/epidemiology ; Female ; Hospitalization ; Humans ; Male ; Middle Aged ; Propensity Score ; Respiration, Artificial/mortality

المؤلفون: Smati S; Department of Endocrinology, Université De Nantes, CHU Nantes, CNRS, INSERM, L'institut Du Thorax, Nantes, France., Canivet CM; Hepato-Gastroenterology department, University Hospital, Angers, France.; HIFIH Laboratory, EA 3859, University of Angers, Angers, France., Boursier J; Hepato-Gastroenterology department, University Hospital, Angers, France.; HIFIH Laboratory, EA 3859, University of Angers, Angers, France., Cariou B; Department of Endocrinology, Université De Nantes, CHU Nantes, CNRS, INSERM, L'institut Du Thorax, Nantes, France.

المصدر: Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2021 Aug; Vol. 30 (8), pp. 813-825. Date of Electronic Publication: 2021 Jul 12.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9434197 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7658 (Electronic) Linking ISSN: 13543784 NLM ISO Abbreviation: Expert Opin Investig Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Diabetes Mellitus, Type 2/*drug therapy , Hypoglycemic Agents/*pharmacology , Non-alcoholic Fatty Liver Disease/*drug therapy, Animals ; Diabetes Mellitus, Type 2/physiopathology ; Drugs, Investigational/pharmacology ; Humans ; Insulin Resistance ; Liver Cirrhosis/drug therapy ; Non-alcoholic Fatty Liver Disease/physiopathology ; Research Design

المؤلفون: Rodbard HW; Endocrine and Metabolic Consultants, Rockville, MD, USA., Giaccari A; Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy., Cariou B; L'institut du thorax, UNIV Nantes, CNRS Inserm, CHU Nantes, Nantes, France., Garg S; Departments of Medicine and Pediatrics, Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO, USA., Davies MJ; Lexicon Pharmaceuticals, Inc., The Woodlands, TX, USA.; Esperion Therapeutics, Ann Arbor, MI, USA., Seth K; Lexicon Pharmaceuticals, Inc., The Woodlands, TX, USA., Sawhney S; Lexicon Pharmaceuticals, Inc., The Woodlands, TX, USA.; Immuvant, Inc., New York, NY, USA.

المصدر: Diabetes & vascular disease research [Diab Vasc Dis Res] 2021 Jan-Feb; Vol. 18 (1), pp. 1479164121995928.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Sage Publications Country of Publication: England NLM ID: 101234011 Publication Model: Print Cited Medium: Internet ISSN: 1752-8984 (Electronic) Linking ISSN: 14791641 NLM ISO Abbreviation: Diab Vasc Dis Res Subsets: MEDLINE

مواضيع طبية MeSH: Blood Glucose/*drug effects , Blood Pressure/*drug effects , Diabetes Mellitus, Type 1/*drug therapy , Glycosides/*therapeutic use , Hypoglycemic Agents/*therapeutic use , Insulin/*therapeutic use , Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use , Vascular Stiffness/*drug effects, Adult ; Biomarkers/blood ; Blood Glucose/metabolism ; Clinical Trials, Phase III as Topic ; Diabetes Mellitus, Type 1/blood ; Diabetes Mellitus, Type 1/diagnosis ; Diabetes Mellitus, Type 1/physiopathology ; Drug Therapy, Combination ; Female ; Glycosides/adverse effects ; Humans ; Hypoglycemic Agents/adverse effects ; Insulin/adverse effects ; Male ; Randomized Controlled Trials as Topic ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Time Factors ; Treatment Outcome ; Vascular Resistance/drug effects

المؤلفون: DeSouza C; University of Nebraska Medical Center, Omaha, NE, US., Cariou B; L'Institut du Thorax, Department of Endocrinology, CHU Nantes, Nantes, France., Garg S; Barbara Davis Center for Diabetes, University of Colorado Denver, Denver, CO, US., Lausvig N; Novo Nordisk A/S, Søborg, Denmark., Navarria A; Novo Nordisk A/S, Søborg, Denmark., Fonseca V; Tulane University Health Sciences Center, New Orleans, LA, US.

المصدر: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2020 Feb 01; Vol. 105 (2).

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited Medium: Internet ISSN: 1945-7197 (Electronic) Linking ISSN: 0021972X NLM ISO Abbreviation: J Clin Endocrinol Metab Subsets: MEDLINE

مواضيع طبية MeSH: Diabetes Mellitus, Type 2/*drug therapy , Ethnicity/*statistics & numerical data , Glucagon-Like Peptides/*administration & dosage , Hypoglycemic Agents/*administration & dosage , Racial Groups/*statistics & numerical data, Adult ; Blood Glucose/drug effects ; Body Weight/drug effects ; Body Weight/ethnology ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/ethnology ; Female ; Glucagon-Like Peptides/analogs & derivatives ; Glycated Hemoglobin/drug effects ; Humans ; Immunoglobulin Fc Fragments/administration & dosage ; Insulin Glargine/administration & dosage ; Male ; Middle Aged ; Recombinant Fusion Proteins/administration & dosage ; Treatment Outcome

المؤلفون: Zinman B; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada zinman@lunenfeld.ca., Aroda VR; Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; MedStar Health Research Institute, Hyattsville, MD., Buse JB; Division of Endocrinology and Metabolism, University of North Carolina School of Medicine, Chapel Hill, NC., Cariou B; Department of Endocrinology, L'Institut du Thorax, CIC INSERM 1413, CHU Nantes, Université de Nantes, Nantes, France., Harris SB; Department of Family Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada., Hoff ST; Novo Nordisk A/S, Søborg, Denmark., Pedersen KB; Novo Nordisk A/S, Søborg, Denmark., Tarp-Johansen MJ; Novo Nordisk A/S, Søborg, Denmark., Araki E

مؤلفون مشاركون: PIONEER 8 Investigators

المصدر: Diabetes care [Diabetes Care] 2019 Dec; Vol. 42 (12), pp. 2262-2271. Date of Electronic Publication: 2019 Sep 17.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Diabetes Association Country of Publication: United States NLM ID: 7805975 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1935-5548 (Electronic) Linking ISSN: 01495992 NLM ISO Abbreviation: Diabetes Care Subsets: MEDLINE

مواضيع طبية MeSH: Diabetes Mellitus, Type 2/*drug therapy , Glucagon-Like Peptides/*administration & dosage , Hypoglycemic Agents/*administration & dosage , Insulin/*administration & dosage , Metformin/*administration & dosage, Adult ; Body Weight/drug effects ; Diabetes Mellitus, Type 2/blood ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Glycated Hemoglobin/drug effects ; Humans ; Male ; Middle Aged ; Nausea/chemically induced ; Treatment Outcome ; Weight Loss/drug effects

المؤلفون: Aroda VR; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: varoda@bwh.harvard.edu., Ahmann A; Harold Schnitzer Diabetes Health Center at Oregon Health and Science University, Portland, OR, USA. Electronic address: ahmanna@ohsu.edu., Cariou B; L'institut du thorax, CHU de Nantes, CIC 1413, Inserm, Nantes, France. Electronic address: bertrand.cariou@univ-nantes.fr., Chow F; Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong. Electronic address: b410773@mailserv.cuhk.edu.hk., Davies MJ; Diabetes Research Centre, University of Leicester, Leicester, UK. Electronic address: melanie.davies@uhl-tr.nhs.uk., Jódar E; Hospital Universitario Quirón Salud Madrid, Facultad de Ciencias de la Salud, Universidad Europea de Madrid, Madrid, Spain. Electronic address: esteban.jodar@gmail.com., Mehta R; Unidad de Investigacón en Enfermedades Metabolicas, Departamento de Endocrinologia y Metablismo, Instituto Nacional de Ciencias Médicas y Nutrición 'Salvador Zubirán' Mexico City, Mexico. Electronic address: roopamehta@yahoo.com., Woo V; Section of Endocrinology and Metabolism, Health Sciences Centre, University of Manitoba, Winnipeg, MB, Canada. Electronic address: vwoo3@shaw.ca., Lingvay I; UT Southwestern Medical Center, Dallas, TX, USA. Electronic address: Ildiko.Lingvay@UTSouthwestern.edu.

المصدر: Diabetes & metabolism [Diabetes Metab] 2019 Oct; Vol. 45 (5), pp. 409-418. Date of Electronic Publication: 2019 Jan 04.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Masson Country of Publication: France NLM ID: 9607599 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1780 (Electronic) Linking ISSN: 12623636 NLM ISO Abbreviation: Diabetes Metab Subsets: MEDLINE

مواضيع طبية MeSH: Diabetes Mellitus, Type 2/*drug therapy , Glucagon-Like Peptide-1 Receptor/*agonists , Glucagon-Like Peptides/*therapeutic use , Hypoglycemic Agents/*therapeutic use , Incretins/*therapeutic use, Glucagon-Like Peptides/adverse effects ; Humans ; Hypoglycemic Agents/adverse effects ; Incretins/adverse effects ; Injections, Subcutaneous ; Treatment Outcome

المؤلفون: Danne T; Diabetes Center, Children and Youth Hospital Auf der Bult, Hannover Medical School, Hannover, Germany., Pettus J; Department of Medicine, University of California San Diego, San Diego, California., Giaccari A; Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy., Cariou B; Department of Endocrinology, L'institut du thorax, Nantes, France., Rodbard H; Endocrine and Metabolic Consultants, Rockville, Maryland., Weinzimer SA; Department of Pediatrics, Yale University, New Haven, Connecticut., Bonnemaire M; Sanofi, Paris, France., Sawhney S; Lexicon Pharmaceuticals, Inc., The Woodlands, Texas., Stewart J; Sanofi US, Inc., Bridgewater, New Jersey., Wang S; Sanofi US, Inc., Bridgewater, New Jersey., Castro RC; Sanofi US, Inc., Bridgewater, New Jersey., Garg SK; Department of Medicine and Pediatrics, Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado.

المصدر: Diabetes technology & therapeutics [Diabetes Technol Ther] 2019 Sep; Vol. 21 (9), pp. 471-477.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 100889084 Publication Model: Print Cited Medium: Internet ISSN: 1557-8593 (Electronic) Linking ISSN: 15209156 NLM ISO Abbreviation: Diabetes Technol Ther Subsets: MEDLINE

مواضيع طبية MeSH: Diabetes Mellitus, Type 1/*drug therapy , Glycated Hemoglobin/*drug effects , Glycosides/*administration & dosage , Hypoglycemia/*epidemiology , Hypoglycemic Agents/*administration & dosage , Insulin/*administration & dosage, Adult ; Blood Glucose/drug effects ; Diabetes Mellitus, Type 1/blood ; Diabetes Mellitus, Type 1/complications ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Hypoglycemia/etiology ; Hypoglycemia/prevention & control ; Male ; Middle Aged ; Sodium-Glucose Transporter 2 Inhibitors/administration & dosage ; Treatment Outcome

المؤلفون: Warren M; Physicians East, Greenville, North Carolina., Chaykin L; Meridien Research, Bradenton, Florida., Trachtenbarg D; University of Illinois College of Medicine at Peoria, Peoria, Illinois., Nayak G; Novo Nordisk A/S, Søborg, Denmark., Wijayasinghe N; Novo Nordisk A/S, Søborg, Denmark., Cariou B; L'Institut du Thorax, Department of Endocrinology, CHU de Nantes, Nantes, France.

المصدر: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Sep; Vol. 20 (9), pp. 2291-2297. Date of Electronic Publication: 2018 Jun 07.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

مواضيع طبية MeSH: Diabetes Mellitus, Type 2/*drug therapy , Glucagon-Like Peptides/*therapeutic use , Hypoglycemic Agents/*therapeutic use, Aged ; Blood Glucose/drug effects ; Body Weight/drug effects ; Diabetes Mellitus, Type 2/blood ; Exenatide/therapeutic use ; Female ; Glycated Hemoglobin/drug effects ; Humans ; Hypoglycemia/chemically induced ; Insulin/therapeutic use ; Male ; Sitagliptin Phosphate/therapeutic use ; Treatment Outcome

المؤلفون: Ray KK; Department of Primary Care and Public Health, Imperial Centre for Cardiovascular Disease Prevention, Imperial College, London, UK., Leiter LA; Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada., Müller-Wieland D; Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany., Cariou B; Department of Endocrinology, l'institut du thorax, CHU Nantes, Nantes, INSERM, CNRS, UNIV Nantes, Nantes, France., Colhoun HM; University of Edinburgh, Edinburgh, UK., Henry RR; University of California San Diego School of Medicine and Center for Metabolic Research, Veterans Affairs, San Diego Healthcare System, San Diego, California., Tinahones FJ; Department of Clinical Endocrinology and Nutrition (IBIMA), Hospital Virgen de la Victoria, University of Málaga, CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Málaga, Spain., Bujas-Bobanovic M; Sanofi, Paris, France., Domenger C; Sanofi, Gentilly, France., Letierce A; Biostatistics and Programming Department, Sanofi, Chilly-Mazarin, France., Samuel R; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Del Prato S; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

المصدر: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Jun; Vol. 20 (6), pp. 1479-1489. Date of Electronic Publication: 2018 Mar 23.

نوع المنشور: Clinical Trial, Phase III; Clinical Trial, Phase IV; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal/*administration & dosage , Anticholesteremic Agents/*administration & dosage , Diabetes Mellitus, Type 2/*drug therapy , Dyslipidemias/*drug therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage , Hypoglycemic Agents/*administration & dosage, Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Anticholesteremic Agents/adverse effects ; Blood Glucose/metabolism ; Cholesterol, HDL/metabolism ; Diabetes Mellitus, Type 2/blood ; Double-Blind Method ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Glycated Hemoglobin/metabolism ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Hypoglycemic Agents/adverse effects ; Lipid Metabolism/drug effects ; Male ; Middle Aged ; Proprotein Convertase 9/metabolism ; Treatment Outcome

المؤلفون: Leiter LA; Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada., Cariou B; Department of Endocrinology, l'institut du thorax, CHU Nantes, INSERM, CNRS, UNIV Nantes, Nantes, France., Müller-Wieland D; Department of Internal Medicine I, University Hospital RWTH Aachen, Aachen, Germany., Colhoun HM; University of Edinburgh, Edinburgh, UK., Del Prato S; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy., Tinahones FJ; Hospital Virgen de la Victoria, CIBERobn, Málaga University, Málaga, Spain., Ray KK; Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK., Bujas-Bobanovic M; Sanofi, Paris, France., Domenger C; Sanofi, Gentilly, France., Mandel J; Sanofi, Chilly-Mazarin, France.; IviData Stats, Levallois-Perret, Paris, France., Samuel R; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Henry RR; University of California San Diego School of Medicine, and Center for Metabolic Research, Veterans Affairs, San Diego Healthcare System, San Diego, California.

المصدر: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2017 Dec; Vol. 19 (12), pp. 1781-1792. Date of Electronic Publication: 2017 Oct 10.

نوع المنشور: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal/*therapeutic use , Anticholesteremic Agents/*therapeutic use , Diabetes Mellitus, Type 1/*drug therapy , Diabetes Mellitus, Type 2/*drug therapy , Hypercholesterolemia/*drug therapy , Hypoglycemic Agents/*therapeutic use , Insulin/*therapeutic use, Aged ; Aged, 80 and over ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Anticholesteremic Agents/administration & dosage ; Anticholesteremic Agents/adverse effects ; Cardiovascular Diseases/complications ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/prevention & control ; Diabetes Mellitus, Type 1/complications ; Diabetes Mellitus, Type 2/complications ; Diabetic Angiopathies/epidemiology ; Diabetic Angiopathies/prevention & control ; Diabetic Cardiomyopathies/epidemiology ; Diabetic Cardiomyopathies/prevention & control ; Double-Blind Method ; Drug Administration Schedule ; Drug Resistance ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hypercholesterolemia/complications ; Injections, Subcutaneous ; Male ; Middle Aged ; Risk